Parmax Pharma Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 3.74 Cr
as on 06-07-2024
- Company Age 30 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.72 Cr
as on 06-07-2024
- Satisfied Charges ₹ 8.24 Cr
as on 06-07-2024
- Revenue -15.56%
(FY 2023)
- Profit -173.54%
(FY 2023)
- Ebitda -11.90%
(FY 2023)
- Net Worth -1.75%
(FY 2023)
- Total Assets -2.01%
(FY 2023)
About Parmax Pharma
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 540359.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 3.74 Cr.
The company currently has active open charges totaling ₹6.72 Cr. The company has closed loans amounting to ₹8.24 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Parmax Pharma Limited India is Keyur Vora as CFO. Nikhil Uchat, Ami Rajeshbhai, and Umang Gosalia serve as directors at the Company.
- CIN/LLPIN
L24231GJ1994PLC023504
- Company No.
023504
- Stock Symbol
BSE : 540359
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Nov 1994
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Rajkot, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Parmax Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umang Gosalia  | Managing Director | 02-Jan-2016 | Current |
| Keyur Vora | CFO | 02-Jan-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ami Rajeshbhai | Director | 17-Jun-2018 | Current |
| Nikhil Uchat | Director | 25-Apr-2023 | Current |
Financial Performance of Parmax Pharma.
Parmax Pharma Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.56% decrease. The company also saw a substantial fall in profitability, with a 173.54% decrease in profit. The company's net worth dipped by a decrease of 1.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parmax Pharma?
In 2021, Parmax Pharma had a promoter holding of 30.80% and a public holding of 69.19%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 May 2023 | ₹6.72 Cr | Open |
Hdfc Bank Limited Creation Date: 08 Feb 2019 | ₹1.12 Cr | Satisfied |
Hdfc Bank Limited Creation Date: 16 Oct 2018 | ₹6.85 Cr | Satisfied |
How Many Employees Work at Parmax Pharma?
Parmax Pharma has a workforce of 9 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parmax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parmax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
